Industry News

The contract development and manufacturing organisation, Recipharm AB (publ) entered into an agreement whereby it will acquire a majority stake in Nitin Lifesciences Limited (“Nitin”), an Indian sterile injectables CMO, currently owned by the Sobti family.

Pharma major Biocon's research arm Syngene International Ltd reported Rs.52 crore net profit for second quarter of fiscal 2015-16 from Rs.40 crore in the same period last year, posting 31 percent annual growth.

Pharma major Biocon on Tuesday reported Rs.306 crore net profit for second quarter of 2015-16, a whopping 200 percent growth over the same period last year due to income from the public issue of its research arm Syngene International Ltd.

Pfizer Inc's subsidiary Hospira has secured an Indian patent for an improved process for the preparation of Cilastatin. Cilastatin is a chemical which acts with anti-biotic Imipenem for the treatment of infections in various body systems. Imipenem and Cilastatin are combined in a drug to make an anti-biotic.  It is used to treat serious infections that are mild to moderate in severity, such as lower respiratory infection and heart valve infection.

U.S. health regulators declined to approve a fixed-dose diabetes drug combination from AstraZeneca, delaying its launch and dealing a blow to an important plank of the drugmaker's business. Food and Drug Administration (FDA) stating that more clinical data were required before it could approve the combination of saxagliptin and dapagliflozin.

PHD Chamber in association with Department of Pharmaceuticals, Ministry of Chemical & Fertilizers organized a Conference on Pharmacology: R&D for Minimizing ADRs and Role of Pharmacists’ 23^rd September 2015, PHD House, New Delhi

Stryker Corporation, one of the world's leading medical technology companies instruments division of interventional spine business unit has received clearance from the US Food and Drug Administration (FDA) to market its expanded indications of VertaPlex HV for the treatment of sacral insufficiency fractures.

U.S. health regulators approved Praxbind, a reversal agent made by Germany Private held Boehringer Ingelheim, for use in emergency situations by patients taking the company's widely used Pradaxa blood thinner. Praxbind, an intravenous injection, is the first reversal agent approved specifically for Pradaxa and works by binding to the drug compound to neutralize it.

Sandoz Canada launch a brand new multi-platform application, which allows healthcare professionals to have this crucial information at their fingertips. Sandoz Pro app (sandozpro.sandoz.ca) allows users to view information on availability of injectable medicines. This new tool is designed for healthcare professionals and buyers who want to make the most of their time, as it helps them plan their injectable drug supplies and make informed decisions at all times.